Yajuan Qin

机构：Providence College, Adc Therapeutics (Switzerland), PTC Therapeutics (United States)

发表论文 13 篇 · 总被引 726 次 · h-index 6

代表论文

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial (2021 · The Lancet Oncology · 被引 430)
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma (2020 · Blood · 被引 175)
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia (2020 · Blood Advances · 被引 57)
Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization (2020 · Science Advances · 被引 29)
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2020 · Blood · 被引 17)
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial (2023 · Blood Advances · 被引 7)